Connect Biopharma Holdings Ltd
Calidad de datos: 100%
CNTB
Nasdaq
Manufacturing
Chemicals
$2.80
▲
$0.17
(6.46%)
Cap. Mercado: 158.26 M
Precio
$2.80
Cap. Mercado
158.26 M
Rango del Día
$2.58 — $2.87
Rango de 52 Semanas
$0.60 — $3.82
Volumen
245,127
Apertura $2.61
Promedio 50D / 200D
$2.71
3.44% above
Promedio 50D / 200D
$2.13
31.68% above
Quick Summary
Puntos Clave
Negative free cash flow of -51.64 M
Capital intensive — 678.13% of revenue goes to capex
Crecimiento
Revenue Growth (5Y)
N/A
Revenue (1Y)-99.75%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
-87.57%
Below sector avg (-53.41%)
ROIC-71.73%
Net Margin-86687.50%
Op. Margin-90740.63%
Seguridad
Debt / Equity
N/A
Current Ratio5.48
Interest CoverageN/A
Valoración
PE (TTM)
-2.85
Below sector avg (-1.48)
P/B Ratio2.86
EV/EBITDAN/A
Dividend YieldN/A
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Manufacturing (1364 pares)
Comparación con Pares
vs mediana del sector Manufacturing (1364 pares)| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -2.9 | -1.5 |
| P/B | 2.9 | 1.6 |
| ROE % | -87.6 | -53.4 |
| Net Margin % | -86687.5 | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -99.75% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 64,000.0 | Net Income (TTM) | -55.48 M |
| ROE | -87.57% | ROA | -73.93% |
| Gross Margin | N/A | Operating Margin | -90740.63% |
| Net Margin | -86687.50% | Free Cash Flow (TTM) | -51.64 M |
| ROIC | -71.73% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 5.48 |
| Interest Coverage | N/A | Asset Turnover | 0.00 |
| Working Capital | 51.17 M | Tangible Book Value | 55.32 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -2.85 | Forward P/E | N/A |
| P/B Ratio | 2.86 | P/S Ratio | 2472.81 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -32.63% | ||
| Market Cap | 158.26 M | Enterprise Value | 120.41 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.00 | Revenue / Share | 0.00 |
| FCF / Share | -0.91 | OCF / Share | -0.91 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 678.13% | FCF Conversion | 93.08% |
| SBC-Adj. FCF | -55.37 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | 64,000.0 | 26.03 M |
| Net Income | -55.48 M | -15.63 M |
| EPS (Diluted) | -1.00 | -0.28 |
| Gross Profit | — | — |
| Operating Income | -58.07 M | -22.45 M |
| EBITDA | — | — |
| R&D Expenses | 37.80 M | 29.26 M |
| SG&A Expenses | — | — |
| D&A | 704,000.0 | 660,000.0 |
| Interest Expense | — | — |
| Income Tax | 197,000.0 | 223,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Total Assets | 56.08 M | 101.28 M |
| Total Liabilities | 14.10 M | 9.12 M |
| Shareholders' Equity | 41.98 M | 92.17 M |
| Total Debt | — | — |
| Cash & Equivalents | 38.35 M | 78.23 M |
| Current Assets | 50.93 M | 96.96 M |
| Current Liabilities | 13.61 M | 8.46 M |
{"event":"ticker_viewed","properties":{"ticker":"CNTB","listing_kind":"stock","pathname":"/stocks/cntb","exchange":"Nasdaq","country":"US"}}